HIF1 α and HIF2 α: sibling rivalry in hypoxic tumour growth and progression

Nature Reviews Cancer

Volumn 12, Issue 1, 2012, Pages 9-22

  Keith, Brian ^a,b   Johnson, Randall S ^c   Simon, M Celeste ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; DAUNORUBICIN; DOXORUBICIN; ECHINOMYCIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; ONCOPROTEIN; RAPAMYCIN; RNA; TEMSIROLIMUS; TOPOTECAN; TRASTUZUMAB;

ACETYLATION; DATA ANALYSIS; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HYPOXIA; NEOPLASM; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; RNA TRANSLATION; TUMOR GROWTH;

ACETYLATION; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL HYPOXIA; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; GENES, MYC; GENES, P53; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEINS;

EID: 84655161946     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3183     Document Type: Review

References (192)

1. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nature Rev. Cancer 3, 721-732 (2003). (Pubitemid 37328811)
2. Bertout, J. A., Patel, S. A. & Simon, M. C. The impact of O2 availability on human cancer. Nature Rev. Cancer 8, 967-975 (2008).
3. Rankin, E. B. & Giaccia, A. J. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 15, 678-685 (2008). (Pubitemid 351405072)
4. Kaelin, W. G. Jr & Ratcliffe, P. J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 30, 393-402 (2008). (Pubitemid 351681994)
5. Majmundar, A. J., Wong, W. J. & Simon, M. C. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 40, 294-309 (2010).
6. Pouyssegur, J., Dayan, F. & Mazure, N. M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441, 437-443 (2006). (Pubitemid 44050138)
7. Wang, G. L., Jiang, B.-H., Rue, E. A. & Semenza, G. L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl Acad. Sci. USA 92, 5510-5514 (1995).
8. Tian, H., McKnight, S. L. & Russell, D. W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11, 72-82 (1997). (Pubitemid 27043825)
9. Flamme, I. et al. HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1α and developmentally expressed in blood vessels. Mech. Dev. 63, 51-60 (1997). (Pubitemid 27214502)
10. Ema, M. et al. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl Acad. Sci. USA 94, 4273-4278 (1997).
11. Hogenesch, J. B. et al. Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway. J. Biol. Chem. 272, 8581-8593 (1997). (Pubitemid 27147824)
12. Wiesener, M. S. et al. Widespread hypoxia-inducible expression of HIF-2α in distinct cell populations of different organs. FASEB J. 17, 271-273 (2003).
13. Makino, Y., Kanopka, A., Wilson, W. J., Tanaka, H. & Poellinger, L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3α locus. J. Biol. Chem. 277, 32405-32408 (2002). (Pubitemid 34984738)
14. Heikkila, M., Pasanen, A., Kivirikko, K. I. & Myllyharju, J. Roles of the human hypoxia-inducible factor (HIF)-3α variants in the hypoxia response. Cell. Mol. Life Sci. 68, 3885-3901 (2011).
15. Tanaka, T., Wiesener, M., Bernhardt, W., Eckardt, K. U. & Warnecke, C. The human HIF (hypoxia-inducible factor)-3α gene is a HIF-1 target gene and may modulate hypoxic gene induction. Biochem. J. 424, 143-151 (2009).
16. Maynard, M. A. et al. Multiple splice variants of the human HIF-3α locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J. Biol. Chem. 278, 11032-11040 (2003). (Pubitemid 36792653)
17. Maynard, M. A. et al. Dominant-negative HIF-3α4 suppresses VHL-null renal cell carcinoma progression. Cell Cycle 6, 2810-2816 (2007). (Pubitemid 350277174)
18. Hirose, K. et al. cDNA cloning and tissue-specific expression of a novel basic helix-loop-helix/PAS factor (Arnt2) with close sequence similarity to the Aryl hydrocarbon receptor nuclear translocator (Arnt). Mol. Cell. Biol. 16, 1706-1713 (1996).
19. Michaud, J. L., DeRossi, C., May, N. R., Holdener, B. C. & Fan, C. ARNT2 acts as the dimerization partner of SIM1 for the development of the hypothalamus. Mech. Dev. 90, 253-261 (2000). (Pubitemid 30042930)
20. Keith, B., Adelman, D. M. & Simon, M. C. Targeted mutation of the murine arylhydrocarbon receptor nuclear translocator 2 (Arnt2) gene reveals partial redundancy with Arnt. Proc. Natl Acad. Sci. USA 98, 6692-6697 (2001). (Pubitemid 32538278)
21. Qin, X. Y. et al. siRNA-mediated knockdown of aryl hydrocarbon receptor nuclear translocator 2 affects hypoxia-inducible factor-1 regulatory signaling and metabolism in human breast cancer cells. FEBS Lett. 585, 3310-3315 (2011).
22. Kaelin, W. G. Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nature Rev. Cancer 8, 865-873 (2008).
23. Maranchie, J. K. et al. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1, 247-255 (2002). (Pubitemid 41039149)
24. Kondo, K., Kim, W. Y., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1, e83 (2003).
25. Acker, T. et al. Genetic evidence for a tumor suppressor role of HIF-2α. Cancer Cell 8, 131-141 (2005). (Pubitemid 41132742)
26. Mazumdar, J. et al. HIF-2α deletion promotes Kras-driven lung tumor development. Proc. Natl Acad. Sci. USA 107, 14182-14187 (2010).
27. Hu, C.J., Wang, L.Y., Chodosh, L. A., Keith, B. & Simon, M. C. Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol. Biol. Cell 23, 9361-9374 (2003). (Pubitemid 37499822)
28. Raval, R. R. et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 25, 5675-5686 (2005). (Pubitemid 40853601)
29. Hu, C. J., Sataur, A., Wang, L., Chen, H. & Simon, M. C. The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1α and HIF-2α. Mol. Biol. Cell 18, 4528-4542 (2007). (Pubitemid 350060179)
30. Lau, K. W., Tian, Y. M., Raval, R. R., Ratcliffe, P. J. & Pugh, C. W. Target gene selectivity of hypoxia-inducible factor-α in renal cancer cells is conveyed by post-DNA-binding mechanisms. Br. J. Cancer 96, 1284-1292 (2007). (Pubitemid 46625064)
31. Xia, X. et al. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc. Natl Acad. Sci. USA 106, 4260-4265 (2009).
32. Xia, X. & Kung, A. L. Preferential binding of HIF-1 to transcriptionally active loci determines cell-type specific response to hypoxia. Genome Biol. 10, R113 (2009).
33. Mole, D. R. et al. Genome-wide association of hypoxia-inducible factor (HIF)-1α and HIF-2α DNA binding with expression profiling of hypoxia-inducible transcripts. J. Biol. Chem. 284, 16767-16775 (2009).
34. Krieg, A. J. et al. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1α enhances hypoxic gene expression and tumor growth. Mol. Cell. Biol. 30, 344-353 (2010).
35. Schodel, J. et al. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood 117, e207-e217 (2011).
36. Iyer, N. V. et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1α. Genes Dev. 12, 149-162 (1998). (Pubitemid 28060446)
37. Ryan, H. E., Lo, J. & Johnson, R. S. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J. 17, 3005-3015 (1998). (Pubitemid 28254373)
38. Tian, H., Hammer, R. E., Matsumoto, A. M., Russell, D. W. & McKnight, S. L. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev. 12, 3320-3324 (1998). (Pubitemid 28520979)
39. Compernolle, V. et al. Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nature Med. 8, 702-710 (2002). (Pubitemid 34778723)
40. Peng, J., Zhang, L., Drysdale, L. & Fong, G. H. The transcription factor EPAS-1/hypoxia-inducible factor 2α plays an important role in vascular remodeling. Proc. Natl Acad. Sci. USA 97, 8386-8391 (2000). (Pubitemid 30639682)
41. Scortegagna, M. et al. Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/-mice. Nature Genet. 35, 331-340 (2003). (Pubitemid 37486916)
42. Gruber, M. et al. Acute postnatal ablation of Hif-2α results in anemia. Proc. Natl Acad. Sci. USA 104, 2301-2306 (2007). (Pubitemid 46391392)
43. Liao, D., Corle, C., Seagroves, T. N. & Johnson, R. S. Hypoxia-inducible factor-1α is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res. 67, 563-572 (2007). (Pubitemid 46192193)
44. Krop, I. et al. HIN-1, an inhibitor of cell growth, invasion, and AKT activation. Cancer Res. 65, 9659-9669 (2005). (Pubitemid 41541441)
45. Kim, W. Y. et al. HIF2α cooperates with RAS to promote lung tumorigenesis in mice. J. Clin. Invest. 119, 2160-2170 (2009).
46. Rankin, E. B. et al. Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice. Oncogene 27, 5354-5358 (2008).
47. Fang, H. Y. et al. Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia. Blood 114, 844-859 (2009).
48. Doedens, A. L. et al. Macrophage expression of hypoxia-inducible factor-1α suppresses T-cell function and promotes tumor progression. Cancer Res. 70, 7465-7475 (2010).
49. Takeda, N. et al. Differential activation and antagonistic function of HIF-α isoforms in macrophages are essential for NO homeostasis. Genes Dev. 24, 491-501 (2010).
50. Imtiyaz, H. Z. et al. Hypoxia-inducible factor 2α regulates macrophage function in mouse models of acute and tumor inflammation. J. Clin. Invest. 120, 2699-2714 (2010).
51. Tang, N. et al. Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6, 485-495 (2004). (Pubitemid 39469984)
52. Yamashita, T. et al. Hypoxia-inducible transcription factor-2α in endothelial cells regulates tumor neovascularization through activation of ephrin A1. J. Biol. Chem. 283, 18926-18936 (2008).
53. Skuli, N. et al. Endothelial deletion of hypoxia-inducible factor-2α (HIF-2α) alters vascular function and tumor angiogenesis. Blood 114, 469-477 (2009).
54. Belaiba, R. S. et al. Hypoxia up-regulates hypoxia-inducible factor-1αtranscription by involving phosphatidylinositol 3-kinase and nuclear factor κB in pulmonary artery smooth muscle cells. Mol. Biol. Cell 18, 4691-4697 (2007).
55. Frede, S., Stockmann, C., Freitag, P. & Fandrey, J. Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-κB. Biochem. J. 396, 517-527 (2006). (Pubitemid 44228166)
56. Nizet, V. & Johnson, R. S. Interdependence of hypoxic and innate immune responses. Nature Rev. Immunol. 9, 609-617 (2009).
57. Rius, J. et al. NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α. Nature 453, 807-811 (2008). (Pubitemid 351793778)
58. Kenneth, N. S., Mudie, S., van Uden, P. & Rocha, S. SWI/SNF regulates the cellular response to hypoxia. J. Biol. Chem. 284, 4123-4131 (2009).
59. Toschi, A., Lee, E., Gadir, N., Ohh, M. & Foster, D. A. Differential dependence of hypoxia-inducible factors 1α and 2α on mTORC1 and mTORC2. J. Biol. Chem. 283, 34495-34499 (2008).
60. Uchida, T. et al. Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1α and HIF-2α expression in lung epithelial cells: implication of natural antisense HIF-1α. J. Biol. Chem. 279, 14871-14878 (2004).
61. Sanchez, M., Galy, B., Muckenthaler, M. U. & Hentze, M. W. Iron-regulatory proteins limit hypoxia-inducible factor-2α expression in iron deficiency. Nature Struct. Mol. Biol. 14, 420-426 (2007). (Pubitemid 46685876)
62. Zimmer, M. et al. Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing. Mol. Cell 32, 838-848 (2008).
63. Lee, F. S. & Percy, M. J. The HIF pathway and erythrocytosis. Annu. Rev. Pathol. 6, 165-192 (2011).
64. Mastrogiannaki, M. et al. HIF-2α, but not HIF-1α, promotes iron absorption in mice. J. Clin. Invest. 119, 1159-1166 (2009).
65. Rankin, E. B. et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J. Clin. Invest. 117, 1068-1077 (2007). (Pubitemid 46556763)
66. Morita, M. et al. HLF/HIF-2α is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J. 22, 1134-1146 (2003). (Pubitemid 36313597)
67. Nilsson, H. et al. HIF-2α expression in human fetal paraganglia and neuroblastoma: relation to sympathetic differentiation, glucose deficiency, and hypoxia. Exp. Cell Res. 303, 447-456 (2005). (Pubitemid 40126276)
68. Holmquist-Mengelbier, L. et al. Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive phenotype. Cancer Cell 10, 413-423 (2006). (Pubitemid 44693470)
69. Li, Z. et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15, 501-513 (2009).
70. Koh, M. Y., Darnay, B. G. & Powis, G. Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1α, leading to its oxygen-independent degradation. Mol. Cell. Biol. 28, 7081-7095 (2008).
71. Koh, M. Y., Lemos, R. Jr, Liu, X. & Powis, G. The hypoxia-associated factor switches cells from HIF-1α-to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res. 71, 4015-4027 (2011).
72. Luo, W. et al. Hsp70 and CHIP selectively mediate ubiquitination and degradation of hypoxia-inducible factor (HIF)-1α but Not HIF-2α. J. Biol. Chem. 285, 3651-3663 (2010).
73. Jokilehto, T. & Jaakkola, P. M. The role of HIF prolyl hydroxylases in tumour growth. J. Cell. Mol. Med. 14, 758-770 (2010).
74. Chan, D. A. & Giaccia, A. J. PHD2 in tumour angiogenesis. Br. J. Cancer 103, 1-5 (2010).
75. Cockman, M. E., Webb, J. D. & Ratcliffe, P. J. FIH-dependent asparaginyl hydroxylation of ankyrin repeat domain-containing proteins. Ann. NY Acad. Sci. 1177, 9-18 (2009).
76. Appelhoff, R. J. et al. Differential function of the prolyl hydroxylases, PHD1, PHD2 and PHD3 in the regulation of hypoxia-inducible factor. J. Biol. Chem. 279, 38458-38465 (2004).
77. Bracken, C. P. et al. Cell-specific regulation of hypoxia-inducible factor (HIF)-1α and HIF-2α stabilization and transactivation in a graded oxygen environment. J. Biol. Chem. 281, 22575-22585 (2006).
78. Zhang, N. et al. The asparaginyl hydroxylase factor inhibiting HIF-1α is an essential regulator of metabolism. Cell Metab. 11, 364-378 (2010).
79. Richard, D. E., Berra, E., Gothie, E., Roux., D. & Pouyssegur, J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 274, 32631-32637 (1999). (Pubitemid 129535289)
80. Conrad, P. W., Freeman, T. L., Beitner-Johnson, D. & Millhorn, D. E. EPAS1 trans-activation during hypoxia requires p42/p44 MAPK. J. Biol. Chem. 274, 33709-33713 (1999). (Pubitemid 129511686)
81. To, K. K., Sedelnikova, O. A., Samons, M., Bonner, W. M. & Huang, L. E. The phosphorylation status of PAS-B distinguishes HIF-1α from HIF-2α in NBS1 repression. EMBO J. 25, 4784-4794 (2006). (Pubitemid 44607024)
82. Mylonis, I. et al. Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1α. J. Biol. Chem. 281, 33095-33106 (2006). (Pubitemid 46043259)
83. Kalousi, A. et al. Casein kinase 1 regulates human hypoxia-inducible factor HIF-1. J. Cell Sci. 123, 2976-2986 (2010).
84. Cam, H., Easton, J. B., High, A. & Houghton, P. J. mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. Mol. Cell 40, 509-520 (2010).
85. Finkel, T., Deng, C. X. & Mostoslavsky, R. Recent progress in the biology and physiology of sirtuins. Nature 460, 587-591 (2009).
86. Dioum, E. M. et al. Regulation of hypoxia-inducible factor 2α signaling by the stress-responsive deacetylase sirtuin 1. Science 324, 1289-1293 (2009).
87. Lim, J. H. et al. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1α. Mol. Cell 38, 864-878 (2010).
88. Chen, R., Dioum, E. M., Hogg, R. T., Gerard, R. D. & Garcia, J. A. Hypoxia increases sirtuin 1 expression in a hypoxia-inducible factor-dependent manner. J. Biol. Chem. 286, 13869-13878 (2011).
89. Sayed, D. & Abdellatif, M. AKT-ing via microRNA. Cell Cycle 9, 3213-3217 (2010).
90. Zhong, L. et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1α. Cell 140, 280-293 (2010).
91. Bell, E. L. & Guarente, L. The SirT3 divining rod points to oxidative stress. Mol. Cell 42, 561-568 (2011).
92. Guzy, R. D. et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab. 1, 401-408 (2005). (Pubitemid 43960623)
93. Mansfield, K. D. et al. Cytochrome C is required for cellular oxygen sensing and hypoxic HIF activation. Cell Metab. 1, 393-399 (2005).
94. Brunelle, J. K. et al. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab. 1, 409-414 (2005). (Pubitemid 43960624)
95. Bell, E. L., Emerling, B. M., Ricoult, S. J. & Guarente, L. SirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production. Oncogene 30, 2986-2996 (2011).
96. Finley, L. W. et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell 19, 416-428 (2011).
97. Jeong, J. W. et al. Regulation and destabilization of HIF-1α by ARD1-mediated acetylation. Cell 111, 709-720 (2002).
98. Yoo, Y. G., Kong, G. & Lee, M. O. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1α protein by recruiting histone deacetylase 1. EMBO J. 25, 1231-1241 (2006).
99. Bilton, R. et al. Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1α and is not induced by hypoxia or HIF. J. Biol. Chem. 280, 31132-31140 (2005). (Pubitemid 41291849)
100. Cheng, J., Kang, X., Zhang, S. & Yeh, E. T. SUMO-specific protease 1 is essential for stabilization of HIF1α during hypoxia. Cell 131, 584-595 (2007). (Pubitemid 350007694)
101. van Hagen, M., Overmeer, R. M., Abolvardi, S. S. & Vertegaal, A. C. RNF4 and VHL regulate the proteasomal degradation of SUMO-conjugated Hypoxia-Inducible Factor-2α. Nucleic Acids Res. 38, 1922-1931 (2010).
102. Bae, S. H. et al. Sumoylation increases HIF-1α stability and its transcriptional activity. Biochem. Biophys. Res. Commun. 324, 394-400 (2004).
103. Carbia-Nagashima, A. et al. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1α during hypoxia. Cell 131, 309-323 (2007). (Pubitemid 47592916)
104. Huang, C. et al. SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 de-SUMOylation. EMBO J. 28, 2748-2762 (2009).
105. Li, F. et al. Regulation of HIF-1α stability through S-nitrosylation. Mol. Cell 26, 63-74 (2007). (Pubitemid 46550936)
106. Ryu, J. H. et al. Hypoxia-inducible factor α subunit stabilization by NEDD8 conjugation is reactive oxygen species-dependent. J. Biol. Chem. 286, 6963-6970 (2011).
107. Koshiji, M. et al. HIF-1α induces cell cycle arrest by functionally counteracting Myc. EMBO J. 23, 1949-1956 (2004). (Pubitemid 38902073)
108. Dang, C. V., Kim, J. W., Gao, P. & Yustein, J. The interplay between MYC and HIF in cancer. Nature Rev. Cancer 8, 51-56 (2008).
109. Koshiji, M. et al. HIF-1α induces genetic instability by transcriptionally downregulating MutSα expression. Mol. Cell 17, 793-803 (2005). (Pubitemid 40386941)
110. Gordan, J. D., Bertout, J. A., Hu, C. J., Diehl, J. A. & Simon, M. C. HIF-2α promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11, 335-347 (2007). (Pubitemid 46518312)
111. Corn, P. G. et al. Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol. Ther. 4, 1285-1294 (2005).
112. Zhang, H. et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11, 407-420 (2007). (Pubitemid 46670080)
113. Gordan, J. D. et al. HIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14, 435-446 (2008).
114. Kim, J. W., Gao, P., Liu, Y. C., Semenza, G. L. & Dang, C. V. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol. Cell. Biol. 27, 7381-7393 (2007). (Pubitemid 350033646)
115. Qing, G. et al. Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1α. Cancer Res. 70, 10351-10361 (2010).
116. Kaelin, W. G. Jr. Kidney cancer: now available in a new flavor. Cancer Cell 14, 423-424 (2008).
117. Vousden, K. H. & Prives, C. Blinded by the light: the growing complexity of p53. Cell 137, 413-431 (2009).
118. Lavin, M. F. & Gueven, N. The complexity of p53 stabilization and activation. Cell Death Differ. 13, 941-950 (2006).
119. Pan, Y., Oprysko, P. R., Asham, A. M., Koch, C. J. & Simon, M. C. p53 cannot be induced by hypoxia alone but responds to the hypoxic microenvironment. Oncogene 23, 4975-4983 (2004). (Pubitemid 38938730)
120. An, W. G. et al. Stabilization of wild-type p53 by hypoxia-inducible factor 1α. Nature 392, 405-408 (1998).
121. Sanchez-Puig, N., Veprintsev, D. B. & Fersht, A. R. Binding of natively unfolded HIF-1α ODD domain to p53. Mol. Cell 17, 11-21 (2005). (Pubitemid 40075361)
122. Chen, D., Li, M., Luo, J. & Gu, W. Direct interactions between HIF-1α and Mdm2 modulate p53 function. J. Biol. Chem. 278, 13595-13598 (2003). (Pubitemid 36799889)
123. Moeller, B. J. et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8, 99-110 (2005). (Pubitemid 41132739)
124. Ravi, R. et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev. 14, 34-44 (2000). (Pubitemid 30051577)
125. Bertout, J. A. et al. HIF2α inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc. Natl Acad. Sci. USA 106, 14391-14396 (2009).
126. Roberts, A. M. et al. Suppression of hypoxia-inducible factor 2α restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res. 69, 9056-9064 (2009).
127. Sengupta, S., Peterson, T. R. & Sabatini, D. M. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol. Cell 40, 310-322 (2010).
128. Menon, S. & Manning, B. D. Common corruption of the mTOR signaling network in human tumors. Oncogene 27 (Suppl. 2), S43-S51 (2008).
129. Liu, L. et al. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol. Cell 21, 521-531 (2006). (Pubitemid 43228007)
130. Brugarolas, J. et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 18, 2893-2904 (2004). (Pubitemid 39602308)
131. DeYoung, M. P., Horak, P., Sofer, A., Sgroi, D. & Ellisen, L. W. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 22, 239-251 (2008).
132. Li, Y. et al. Bnip3 mediates the hypoxia-induced inhibition on mammalian target of rapamycin by interacting with Rheb. J. Biol. Chem. 282, 35803-35813 (2007). (Pubitemid 350277153)
133. Gan, B., Melkoumian, Z. K., Wu, X., Guan, K. L. & Guan, J. L. Identification of FIP200 interaction with the TSC1-TSC2 complex and its role in regulation of cell size control. J. Cell Biol. 170, 379-389 (2005). (Pubitemid 41126938)
134. Chano, T. et al. Neuromuscular abundance of RB1CC1 contributes to the non-proliferating enlarged cell phenotype through both RB1 maintenance and TSC1 degradation. Int. J. Mol. Med. 18, 425-432 (2006).
135. Morris, M. R. et al. Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma. Anticancer Res. 29, 4337-4343 (2009).
136. Dalgliesh, G. L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360-363 (2010).
137. Beroukhim, R. et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 69, 4674-4681 (2009).
138. Purdue, M. P. et al. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nature Genet. 43, 60-65 (2010).
139. Semenza, G. L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29, 625-634 (2010).
140. Rapisarda, A. et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62, 4316-4324 (2002). (Pubitemid 34827288)
141. Lee, K. et al. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc. Natl Acad. Sci. USA 106, 17910-17915 (2009).
142. Majumder, P. K. et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Med. 10, 594-601 (2004). (Pubitemid 38796850)
143. Thomas, G. V. et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nature Med. 12, 122-127 (2006). (Pubitemid 43050086)
144. Kong, X. et al. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1α. Mol. Cell. Biol. 26, 2019-2028 (2006). (Pubitemid 43346906)
145. Qian, D. Z. et al. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α. Cancer Res. 66, 8814-8821 (2006). (Pubitemid 44449199)
146. Isaacs, J. S. et al. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway. J. Biol. Chem. 277, 29936-29944 (2002).
147. Mabjeesh, N. J. et al. Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells. Cancer Res. 62, 2478-2482 (2002). (Pubitemid 34462721)
148. Moeller, B. J., Cao, Y., Li, C. Y. & Dewhirst, M. W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5, 429-441 (2004). (Pubitemid 38610245)
149. Lando, D. et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16, 1466-1471 (2002). (Pubitemid 34686328)
150. Mahon, P. C., Hirota, K. & Semenza, G. L. FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15, 2675-2686 (2001). (Pubitemid 32988878)
151. Hewitson, K. S. et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J. Biol. Chem. 277, 26351-26355 (2002). (Pubitemid 34967127)
152. Simon, M. C. & Keith, B. The role of oxygen availability in embryonic development and stem cell function. Nature Rev. Mol. Cell Biol. 9, 285-296 (2008). (Pubitemid 351430845)
153. Mazumdar, J. et al. O2 regulates stem cells through Wnt/β-catenin signalling. Nature Cell Biol. 12, 1007-1013 (2010).
154. Kaidi, A., Williams, A. C. & Paraskeva, C. Interaction between β-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nature Cell Biol. 9, 210-217 (2007). (Pubitemid 46420864)
155. Gustafsson, M. V. et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev. Cell 9, 617-628 (2005). (Pubitemid 41555144)
156. Bertout, J. A. et al. Heterozygosity for hypoxia inducible factor 1α decreases the incidence of thymic lymphomas in a p53 mutant mouse model. Cancer Res. 69, 3213-3220 (2009).
157. Pietras, A. et al. HIF-2α maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. Proc. Natl Acad. Sci. USA 106, 16805-16810 (2009).
158. Covello, K. L. et al. HIF-2α regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 20, 557-570 (2006). (Pubitemid 43345322)
159. Gilbertson, R. J. & Rich, J. N. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nature Rev. Cancer 7, 733-736 (2007). (Pubitemid 47463683)
160. Semenza, G. L. HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev. 20, 51-56 (2010).
161. Korkolopoulou, P. et al. Hypoxia-inducible factor 1α/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol. Appl. Neurobiol. 30, 267-278 (2004). (Pubitemid 38789248)
162. Scrideli, C. A. et al. Prognostic significance of co-overexpression of the EGFR/IGFBP-2/HIF-2A genes in astrocytomas. J. Neurooncol. 83, 233-239 (2007). (Pubitemid 46952233)
163. Theodoropoulos, V. E. et al. Hypoxia-inducible factor 1α expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur. Urol. 46, 200-208 (2004). (Pubitemid 38902737)
164. Yamamoto, Y. et al. Hypoxia-inducible factor 1α is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res. Treat. 110, 465-475 (2008). (Pubitemid 351962589)
165. Helczynska, K. et al. Hypoxia-inducible factor-2α correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res. 68, 9212-9220 (2008).
166. Birner, P. et al. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 60, 4693-4696 (2000).
167. Kawanaka, T. et al. Prognostic significance of HIF-2α expression on tumor infiltrating macrophages in patients with uterine cervical cancer undergoing radiotherapy. J. Med. Invest. 55, 78-86 (2008). (Pubitemid 351643597)
168. Yoshimura, H. et al. Prognostic impact of hypoxia-inducible factors 1α and 2α in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin. Cancer Res. 10, 8554-8560 (2004). (Pubitemid 40053424)
169. Griffiths, E. A. et al. Hypoxia-inducible factor-1α expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br. J. Cancer 96, 95-103 (2007). (Pubitemid 46094645)
170. Griffiths, E. A. et al. Hypoxia-associated markers in gastric carcinogenesis and HIF-2α in gastric and gastro-oesophageal cancer prognosis. Br. J. Cancer 98, 965-973 (2008). (Pubitemid 351341598)
171. Mizokami, K., Kakeji, Y., Oda, S. & Maehara, Y. Relationship of hypoxia-inducible factor 1α and p21WAF1/CIP1 expression to cell apoptosis and clinical outcome in patients with gastric cancer. World J. Surg. Oncol. 4, 94 (2006).
172. Takahashi, R. et al. Hypoxia-inducible factor-1α expression and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncol. Rep. 10, 797-802 (2003).
173. Koukourakis, M. I. et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 53, 1192-1202 (2002). (Pubitemid 34787855)
174. Winter, S. C. et al. The relation between hypoxia-inducible factor (HIF)-1α and HIF-2α expression with anemia and outcome in surgically treated head and neck cancer. Cancer 107, 757-766 (2006). (Pubitemid 44232668)
175. Bangoura, G. et al. Prognostic significance of HIF-2α/EPAS1 expression in hepatocellular carcinoma. World J. Gastroenterol. 13, 3176-3182 (2007). (Pubitemid 47064579)
176. Giatromanolaki, A. et al. Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br. J. Cancer 85, 881-890 (2001). (Pubitemid 33010557)
177. Kim, S. J. et al. Expression of HIF-1α, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 49, 325-335 (2005). (Pubitemid 41139145)
178. Wu, X. H., Qian, C. & Yuan, K. Correlations of hypoxia-inducible factor-1α/hypoxia-inducible factor-2α expression with angiogenesis factors expression and prognosis in non-small cell lung cancer. Chin. Med. J. 124, 11-18 (2011).
179. Giatromanolaki, A. et al. Hypoxia-inducible factors 1α and 2α are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res. 13, 493-501 (2003). (Pubitemid 37266952)
180. Noguera, R. et al. HIF-1α and HIF-2α are differentially regulated in vivo in neuroblastoma: high HIF-1α correlates negatively to advanced clinical stage and tumor vascularization. Clin. Cancer Res. 15, 7130-7136 (2009).
181. Daponte, A. et al. Prognostic significance of Hypoxia-Inducible Factor 1α (HIF-1α) expression in serous ovarian cancer: an immunohistochemical study. BMC Cancer 8, 335 (2008).
182. Osada, R. et al. Expression of hypoxia-inducible factor 1α, hypoxia-inducible factor 2α, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1α is an independent prognostic factor in ovarian carcinoma. Hum. Pathol. 38, 1310-1320 (2007). (Pubitemid 47247486)
183. Sun, H. C. et al. Expression of hypoxia-inducible factor-1α and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int. J. Oncol. 30, 1359-1367 (2007).
184. Shibaji, T. et al. Prognostic significance of HIF-1α overexpression in human pancreatic cancer. Anticancer Res. 23, 4721-4727 (2003). (Pubitemid 38173890)
185. Nanni, S. et al. Endothelial NOS, estrogen receptor β, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J. Clin. Invest. 119, 1093-1108 (2009).
186. Lidgren, A. et al. The expression of hypoxia-inducible factor 1α is a favorable independent prognostic factor in renal cell carcinoma. Clin. Cancer Res. 11, 1129-1135 (2005). (Pubitemid 40175762)
187. Klatte, T. et al. Hypoxia-inducible factor 1α in clear cell renal cell carcinoma. Clin. Cancer Res. 13, 7388-7393 (2007).
188. Kapitsinou, P. P. et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood 116, 3039-3048 (2010).
189. Gunaratnam, L. et al. Hypoxia inducible factor activates the transforming growth factor-α/epidermal growth factor receptor growth stimulatory pathway in VHL-/-renal cell carcinoma cells. J. Biol. Chem. 278, 44966-44974 (2003). (Pubitemid 37377256)
190. Carmeliet, P. et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485-490 (1998). (Pubitemid 28373960)
191. Ryan, H. E. et al. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res. 60, 4010-4015 (2000). (Pubitemid 30636574)
192. Kondo, K., Klco, J., Nakamura, E., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1, 237-246 (2002). (Pubitemid 41039148)